Regeneron Pharmaceuticals Inc stock (US7739031091): valuation metrics in focus after recent trading

Regeneron Pharmaceuticals Inc shares on Nasdaq remain in focus as investors assess the biotech group’s latest earnings, valuation ratios and pipeline collaborations, including recent financing activity involving a partner company in the United States.

Regeneron Pharmaceuticals Inc shares trade on the Nasdaq in the United States, where the stock gives investors exposure to one of the country’s larger independent biotechnology companies with a strong focus on antibody-based therapeutics and ophthalmology treatments.

The stock traded at USD 1,099.65 on 05/03/2026 on Nasdaq under the ticker REGN, according to Nasdaq as of 05/03/2026, following the company’s latest quarterly report for the period ended 03/31/2026 and subsequent investor updates.Nasdaq as of 05/03/2026

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: REGN
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Tarrytown, United States
• Core markets: United States, Europe, Japan and other international markets
• Key revenue drivers: Ophthalmology, immunology, oncology and rare-disease medicines
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharmaceuticals Inc: core business model

Regeneron Pharmaceuticals Inc focuses on discovering and developing biologic medicines, with revenue primarily generated from the commercialization of therapies for eye diseases, inflammatory conditions, cancer and other serious illnesses, supported by collaborations with larger pharmaceutical partners.

Valuation metrics and multiples for Regeneron Pharmaceuticals Inc

Investors looking at Regeneron Pharmaceuticals Inc on 05/03/2026 were assessing the stock’s valuation following the company’s publication of results for the quarter ended 03/31/2026, which showed revenue of USD 3.53 billion and diluted earnings per share of USD 11.23, according to the company’s press release dated 05/02/2026.Regeneron investor relations as of 05/02/2026

Based on the closing price of USD 1,099.65 on Nasdaq on 05/03/2026 and the trailing twelve-month diluted earnings per share reported as USD 45.60 in the same 05/02/2026 release, Regeneron Pharmaceuticals Inc was trading at a trailing price-earnings ratio of approximately 24.1 on that date, according to calculations using figures from the company and Nasdaq as of 05/03/2026.

Using the same share price of USD 1,099.65 on 05/03/2026 and a reported cash and marketable securities position of USD 16.2 billion at 03/31/2026 from the 05/02/2026 financial update, some investors may focus on enterprise-value-based multiples for Regeneron Pharmaceuticals Inc when comparing it with United States large-cap biotechnology peers.

Alongside earnings-based valuation measures, market participants in the United States and Europe also monitor how Regeneron Pharmaceuticals Inc is valued relative to sales, with the 05/02/2026 release indicating total revenue of USD 13.48 billion for full-year 2025, which yields a price-to-sales ratio near 6.6 using the 05/03/2026 Nasdaq closing price.

On the capital markets side, investors in Regeneron Pharmaceuticals Inc may also take note of transactions involving partners in its broader ecosystem; for example, on 06/05/2026 BioWorld reported that Parabilis Medicines, which has a collaboration with Regeneron Pharmaceuticals Inc around the peptide drug candidate zolucatetide for desmoid tumors, filed for a United States initial public offering targeting proceeds of up to USD 475 million.BioWorld as of 06/05/2026

While that planned listing belongs to Parabilis Medicines rather than Regeneron Pharmaceuticals Inc, the financing round described on 06/05/2026 underscores the ongoing capital formation environment for clinical-stage biotechs that are partnered with larger companies such as Regeneron in the United States.

Conclusion

For investors following United States-listed biotechnology names, Regeneron Pharmaceuticals Inc offers a combination of established revenue streams and ongoing clinical development that feeds into valuation metrics such as price-earnings and price-to-sales ratios derived from its 05/02/2026 financial update.

The company’s profile on Nasdaq on 05/03/2026, as well as transactional activity around partners like Parabilis Medicines noted on 06/05/2026, provides additional context for how market participants may compare Regeneron Pharmaceuticals Inc to other large-cap biotech stocks when considering relative valuation.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.